glp-1 news october 21 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Drugs: 2026 Pulse Survey
Description
By exploring human studies and mechanistic insights, this review underscores irisins potential to address global health challenges, such as obesity and type 2 diabetes, while advancing strategies for personalized exercise interventions.
Understanding why provider guidance matters helps patients access these medications responsibly through appropriate channels
Moreover, the addition of finerenone to this combination therapy could potentially provide stronger cardiorenal protective benefits
The approval could expand access to an effective therapy for managing obesity.
